Kidney Week

Abstract: SA-PO658

Superior Effects of Etelcalcetide Compared to Cinacalcet on Increasing Bone Mineral Density in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism

Session Information

• Bone and Mineral Metabolism: Clinical - II
  October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

• 402 Bone and Mineral Metabolism: Clinical

Authors

• Funakoshi, Satoshi, Nagasaki Kidney Hospital, Nagasaki, Japan

Satoshi Funakoshi,

• Hashiguchi, Jyunichiro, Nagasaki Kidney Hospital, Nagasaki, Japan

Jyunichiro Hashiguchi,

• Kawazu, Tayo, Nagasaki Kidney Hospital, Nagasaki, Japan

Tayo Kawazu,

• Sawase, Kenji, Nagasaki Kidney Hospital, Nagasaki, Japan

Kenji Sawase,

• Maruyama, Yuko, Nagasaki Kidney Hospital, Nagasaki, Japan

Yuko Maruyama,

• Obata, Yoko, Nagasaki University Hospital, Nagasaki, Japan

Yoko Obata,

• Nishino, Tomoya, Nagasaki University School of Medicine, Nagasaki, NAGASAKI, Japan

Tomoya Nishino,

• Harada, Takashi, Nagasaki Kidney Hospital, Nagasaki, Japan

Takashi Harada,

Background

Etelcalcetide hydrochloride (ET) is a novel peptide calcimimetic agent that has a similar mechanism of action as cinacalcet hydrochloride (CT). Clinical trials have demonstrated the safety and efficacy of ET in hemodialysis (HD) patients. In this study we evaluated the efficacy of ET on increasing bone mineral density (BMD) in HD patients with secondary hyperparathyroidism (SHPT).

Methods

Ten HD patients with SHPT (M/F: 6/4, mean age: 61.9 years, mean HD duration: 10.3 months) who received oral CT were enrolled in this study after their informed consent was obtained. Various doses of oral CT were converted to 5mg of intravenous ET, and bone resorption markers; TRCP-5b, NTx and bone formation marker; BAP were compared in each patient. BMD was assessed 6 months after conversion to ET treatment by digital image processing (DIP).

Results

As shown in figure, significant declines (p<0.05) were observed in serum levels of TRCP-5b and NTx (from 710.0 ± 289.0 to 420.9 ± 221.1 mU/dL, from 179.6 ± 35.5 to 112.1 ± 26.1 nmol BCE/L, respectively). On the other hand, there was no significant change in serum BAP level. Notably, BMD was significantly increased 6 months after ET treatment was started (p<0.05).

Conclusion

In our study, significant decrease of bone resorption markers, TRCP-5b and NTx, along with no alteration of BAP as a bone formation marker may explain the significant increase in BMD in HD patients with SHPT.

Funding

• Private Foundation Support